tirzepatide and semaglutide therapeutic modality Comparative safety side effects of semaglutide and tirzepatide: Implications for clinical decision-making in obesity management Ozempic® (semaglutide) and Mounjaro™ (tirzepatide),
Description
Sensitivity analyses focusing exclusively on GLP-1 RAs showed consistent results, with a 44% reduction in the risk of reaching the composite IBD outcome (adjusted IRR: 0.56, 95% CI: 0.390.83)
This is a real consideration for people on the standard titration schedule who will eventually reach 10mg or 15mg doses
If you experience any suspected side effects from Ozempic, report them via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or the Yellow Card app)
Normalization of obesity-associated insulin resistance through immunotherapy
